OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

Traders moving in 32.5p on the bid.

RAVEN - 8 Jan'06 - 18:08 - 348 of 348


https://registration.ft.com/registration/barrier?referer=http://search.ft.com/search/totalSearch_Form.html?vsc_appId=ts&symb=&ftsite=FTCOM&searchtype=equity&vsc_query=oxford+biomedica&searchOption=news&location=http%3A//news.ft.com/cms/s/0536a30c-7f23-11da-a6a2-0000779e2340.html&location=http%3A//news.ft.com/cms/s/0536a30c-7f23-11da-a6a2-0000779e2340.html

----------------------

The deal could come as early as this week, this would place another 15p on the share price to around 45p.

RAVEN - 8 Jan'06 - 18:08 - 348 of 349


https://registration.ft.com/registration/barrier?referer=http://search.ft.com/search/totalSearch_Form.html?vsc_appId=ts&symb=&ftsite=FTCOM&searchtype=equity&vsc_query=oxford+biomedica&searchOption=news&location=http%3A//news.ft.com/cms/s/0536a30c-7f23-11da-a6a2-0000779e2340.html&location=http%3A//news.ft.com/cms/s/0536a30c-7f23-11da-a6a2-0000779e2340.html

----------------------

The deal could come as early as this week, this would place another 15p on the share price to around 45p.

RAVEN - 9 Jan'06 - 08:52 - 349 of 349


Very strong start for the week ahead. I repeat again, the T.A is excellent and at the very start of a solid uptrend with the cross almost in place up to 40p

May be lucky to buiy on any dip 33p-33.5p. Target 40p-45p on TA and without news.More immediate target 34p-36p

Pushed higher 33.5p-34p.Likely to be re-rated buy to strong buy based on chart and ma if closes above 32.5p.

Oxford Biomedica PLC
26 January 2006


Oxford BioMedica plc (the 'Company')

Holdings in Company


The Company was notified on 25 January 2006 by UBS AG ('UBS') that following
recent purchases, at close of business on 24 January 2006, acting through its
business group and legal entities listed below, UBS had an interest in
15,911,039 of the Company's ordinary shares of 1p each, representing 3.19 per
cent. of the issued ordinary share capital.


UBS business group/legal entity Shares %

UBS AG London Branch 14,642,856 2.94
UBS Global Asset Management Life Limited 1,268,183 0.25
UBS AG - Total 15,911,039 3.19


None of the Relevant Shares are shares in which UBS is interested by virtue of
Section 208(5) of the Companies Act 1985.

OXB has not broken out...............yet.UBS declared no notifiable interest a few days ago and back above 3% today. Chart and rising trend intact.Support holding @{ 30p and waiting for hold and break above 33p.

badday - 26 Jan'06 - 21:18 - 29262 of 29263


Scottie, not exactly the queens english, but i suspect that qpr will be very right!
There's an enormous amount of news building up, which could come at any time.

Dept of Health Funding
SPA approval from FDA for Trovax phase111 trials
Trovax deal
Approval for Prosavin trials
Metxia results
Additional funding for Monudin
And of course the usual surprises from Retinostat and Lentivectors.
With Results and AGM etc thrown into the pot the coming months should certainly not be lacking in interest.


8 Mar 2006 Center for Business Intelligence Gene Therapy Research Symposium
Cambridge, Massachusetts, USA

8-10 Mar 2006 BioSquare 2006
Geneva, Switzerland

28-30 Mar 2006 British Society for Gene Therapy (BSGT) Meeting
London, UK

29-30 Mar 2006 Ocular Anti-angiogenesis Meeting
London, UK

1-8 Apr 2006 58th Annual American Academy of Neurology Meeting
San Diego, California, USA

9-12 Apr 2006 BIO 2006 Annual International Convention
Chicago, Illinois, USA

30 Apr-4 May 2006 Association for Research in Vision and Ophthalmology (ARVO) 2006 Annual Meeting
Fort Lauderdale, Florida, USA



qpr67 - 26 Jan'06 - 21:25 - 29263 of 29263


badday

One more to note :

5-7 Feb 2006 4th Annual BioPartnering North America (BPN) Conference
Vancouver, Canada

http://www.britishbulls.com/StockPage.asp?CompanyTicker=OXB&MarketTicker=HEALTH%20CARE&Typ=S


OXB

Oxford BioMedica PLC
Daily Commentary


Our system posted a BUY CONFIRMED today. The previous SELL recommendation that was confirmed was made on 20.02.2006 (9) days ago, when the stock price was 31.2500. Since then OXB has gained 0.00% .

Were you eager to go long? Well, without doubt, it was the right time to do so. The BUY signal was finally confirmed, and most probably you have called your broker and placed your long orders with no hesitation.

Don't worry if you have missed this buying opportunity. The market may now give you a second chance. You may still find good prices for buying in the next session.

[MOTTO OF THE DAY]
Buying was right in a nice bullish day
Hold your stocks now whatever they say



BUY
CONFIRMED


31.250
+0.2500 +0.81%

Candlestick Analysis

Todays Candlestick Patterns:

Short White Candlestick

Today a Short White Candlestick was formed. This represents relatively weak buying pressure with little price movement.

It's been a long time since anyone's had anything to say about OXB. I'm assuming the lack of interest and southwards drift of the sp is down to the lack of newsflow?

I think it is one of those stocks which we quietly support for two good reasons - a major cancer breakthrough and as a result of that - a nice little earner

True. But will it be 2006 or 2066?!!

So what do we read into "someone" selling over 11 mil to-day and the SP rises 7%

I have no idea but if they fancy selling 11 mil agan tomorrow we'll be back over 30p!

Gene therapy group Oxford BioMedica said it had received a Special Protocol Assessment agreement from the FDA. The agreement was made for a phase III trial of TroVax, its renal cell carcinoma treatment and paves the way for the start of the trial in the second of this year. Meanwhile, discussions are ongoing with regards to trials in Europe. The shares ended the final session of the week 1.25p lower at 29.25p.

KD.

anyone bought rgt, news looks good

OAK -It's probably EVO manipulating the SP.

Expect some huge buying of OXB at this price, it's been the target for the institutions to trade back to 35-40 and starts here, a licence deal is around the corner and there is at least one large Pharmaceutical co eyeing them up. Trial in Europe will also be announced shortly...

I certainly hope so robstuff. I've tucked these away for the best part of 3 years now and it's been depressing to see them meander back to the price I bought them at but I still believe so I hope you're right!

More excellent news - overlooked by the market but adds value.

Broadly positive news released on Monday. I guess the second part of the message may account for the recent decline in sp but there appear to be a number of irons in the fire regarding a potential partner which bodes well going forward:

Oxford, UK - 31 July 2006: Oxford BioMedica today issues an update on TroVax, the Company's leading cancer immunotherapy product. The update provides information on progress with clinical trial programmes and a marketing partner deal for TroVax.

The Board is pleased to confirm that the TroVax clinical development plan is on
track with appropriate regulatory submissions being made and trial centres for
the phase III TRIST study being set up in the US and Western and Eastern Europe.
Other product development programmes are also progressing according to plan. A
full update will be given with the Company's interim results on 5 September 2006.

A number of shareholders have asked for information on progress towards a TroVax
deal. The Company is in active discussions with a number of potential commercial
partners for TroVax. Inevitably those discussions are highly sensitive. All the
potential partners are substantial companies and have the capability to support
the Company's plans for TroVax and the successful marketing of this product.

Clarification as regards Therion Biologics

The Company has noted some speculation in the market that the failure of
clinical trials of PANVAC-VF, developed by the privately owned United States
company, Therion Biologics, might suggest that phase III trials of TroVax will
not be successful.


Although the Directors do not have access to detailed information on the
PANVAC-VF study, they wish to make the following comments:

While PANVAC-VF uses a similar viral delivery system to TroVax, the active
antigenic components of TroVax are completely different to those used in
PANVAC-VF. PANVAC-VF comprises CEA and Muc-1 whereas TroVax comprises the Company's proprietary antigen, 5T4.
The PANVAC-VF phase III study was in pancreatic cancer patients who had
already failed chemotherapy. This is a particularly challenging target where
no product has shown a survival benefit. In the case of a vaccine the
problem is that the patients' disease advances significantly before a strong
immune response has time to be established by the product. The planned
TroVax phase III TRIST trial is in advanced renal cell cancer patients who
will have received no prior therapy for their metastatic disease and who
have a median survival, with current care, of about 12 months. As has been
shown in a number of phase I/II and phase II studies of TroVax, this is
ample time for an immune response to be established.

In summary, the Directors do not believe that data from the PANVAC-VF trial have
a significant bearing on the future of TroVax.